Literature DB >> 11981294

Abuse and toxicity of methylphenidate.

Wendy Klein-Schwartz1.   

Abstract

The therapeutic use of methylphenidate for the management of attention-deficit hyperactivity disorder in children is increasing. As therapeutic use increases, the risk increases of unintentional overdoses, medication errors, and intentional overdoses caused by abuse, misuse, or suicide gestures and attempts. Side effects during therapy, which include nervousness, headache, insomnia, anorexia, and tachycardia, increase linearly with dose. Clinical manifestations of overdoses include agitation, hallucinations, psychosis, lethargy, seizures, tachycardia, dysrhythmias, hypertension, and hyperthermia. Methylphenidate tablets can be abused orally, or they can be crushed and the powder injected or snorted. Despite its abuse potential, there is disagreement regarding the extent to which methylphenidate is being diverted from legitimate use to abuse in preteens and adolescents.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11981294     DOI: 10.1097/00008480-200204000-00013

Source DB:  PubMed          Journal:  Curr Opin Pediatr        ISSN: 1040-8703            Impact factor:   2.856


  36 in total

Review 1.  Understanding the risk of using medications for attention deficit hyperactivity disorder with respect to physical growth and cardiovascular function.

Authors:  Benedetto Vitiello
Journal:  Child Adolesc Psychiatr Clin N Am       Date:  2008-04

Review 2.  Evolution of stimulants to treat ADHD: transdermal methylphenidate.

Authors:  Kennerly S Patrick; Arthur B Straughn; Jeb S Perkins; Mario A González
Journal:  Hum Psychopharmacol       Date:  2009-01       Impact factor: 1.672

3.  Chronic methylphenidate administration alters antioxidant defenses and butyrylcholinesterase activity in blood of juvenile rats.

Authors:  Felipe Schmitz; Emilene Barros da Silva Scherer; Maira Jaqueline da Cunha; Aline Andrea da Cunha; Daniela Delwing Lima; Débora Delwing; Carlos Alexandre Netto; Angela Terezinha de Souza Wyse
Journal:  Mol Cell Biochem       Date:  2011-10-20       Impact factor: 3.396

4.  Topiramate Confers Neuroprotection Against Methylphenidate-Induced Neurodegeneration in Dentate Gyrus and CA1 Regions of Hippocampus via CREB/BDNF Pathway in Rats.

Authors:  Majid Motaghinejad; Manijeh Motevalian; Mohammad Abdollahi; Mansour Heidari; Zahra Madjd
Journal:  Neurotox Res       Date:  2017-01-11       Impact factor: 3.911

Review 5.  A review of OROS methylphenidate (Concerta(®)) in the treatment of attention-deficit/hyperactivity disorder.

Authors:  Martin A Katzman; Tia Sternat
Journal:  CNS Drugs       Date:  2014-11       Impact factor: 5.749

Review 6.  Treatment of attention deficit hyperactivity disorder in children and adolescents: safety considerations.

Authors:  Mark L Wolraich; Laura McGuinn; Melissa Doffing
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

7.  Acute and sub-chronic functional neurotoxicity of methylphenidate on neural networks in vitro.

Authors:  K V Gopal; B R Miller; G W Gross
Journal:  J Neural Transm (Vienna)       Date:  2007-06-18       Impact factor: 3.575

8.  Neuroprotective effects of various doses of topiramate against methylphenidate-induced oxidative stress and inflammation in isolated rat amygdala: the possible role of CREB/BDNF signaling pathway.

Authors:  Majid Motaghinejad; Manijeh Motevalian; Reza Falak; Mansour Heidari; Mahshid Sharzad; Elham Kalantari
Journal:  J Neural Transm (Vienna)       Date:  2016-09-24       Impact factor: 3.575

9.  Increased cortisol after stress is associated with variability in response time in ADHD children.

Authors:  Seung Hye Lee; Dong-Won Shin; Mark A Stein
Journal:  Yonsei Med J       Date:  2010-02-12       Impact factor: 2.759

10.  Acetyl-L-carnitine reduces impulsive behaviour in adolescent rats.

Authors:  Walter Adriani; Monica Rea; Marta Baviera; William Invernizzi; Mirjana Carli; Orlando Ghirardi; Antonio Caprioli; Giovanni Laviola
Journal:  Psychopharmacology (Berl)       Date:  2004-05-08       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.